Published in final edited form as:

Org Lett. 2012 August 17; 14(16): 4038–4041. doi:10.1021/ol300683r.

Synthesis of Frame-Shifted Farnesyl Diphosphate Analogs

Andrew T. Placzek, James L. Hougland[‡], Richard A. Gibbs^{*}

Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907

[‡]Department of Chemistry, Syracuse University, Syracuse, New York 13244-4100

Abstract

$$x = 0, 1, 2; y = 0, 1, 2; z = 1, 2$$

A set of synthetic approaches was developed and applied to the synthesis of eight frame-shifted farnesyl diphosphate (FPP) analogs. These analogs bear increased or decreased methylene units between the double bonds and/or diphosphate moieties of the isoprenoid structure. Evaluation versus mammalian FTase revealed that small structural changes can lead to dramatic changes in substrate ability.

Isoprenoid diphosphates play major roles as biosynthetic intermediates in both prokaryotes and eukaryotes. They serve as precursors for a diverse set of lipid moieties, including sterols,¹ lipid anchors for carbohydrates,² and lipid anchors for proteins.³ Perhaps the most interesting set of isoprenoid products are the cyclic sesquiterpenes generated from FPP (farnesyl diphosphate or pyrophosphate), due to their diversity,⁴ their unique and promising pharmacological properties,⁵ and the intriguing mechanisms of the sesquiterpene cyclases.⁶ Thus, there is significant continuing interest in the preparation of FPP analogs as probes of these diverse and important processes, and the development of new synthetic routes to these analogs.

Our laboratory has a long-standing interest in the development of new methods for the preparation of FPP analogs, and the use of these analogs as probes for the prenylation of proteins by protein-farnesyltransferase (FTase).³ We have developed methods for the preparation of FPP analogs substituted at the 3 and 7 positions,^{7,8} leading to both potent inhibitors of FTase⁹ and novel chemical probes.¹⁰ Our goal in this study was to alter the structure of FPP in a different manner, by increasing and/or decreasing the carbon spacers in its backbone. These analogs will probe the importance of interactions between the central

^{*}rgibbs@purdue.edu.

Supporting Information Available: Spectral data (¹H-NMR, ¹³C-NMR, LRMS, HRMS) for all newly synthesized compounds; detailed experimental procedures for the synthesis of **3**, **5**, **8-11**, **13**, **15**, **24**, and **34**. ¹H-NMR, ¹³C-NMR spectra for all compounds excluding diphosphates (**11**, **12**, **19**, **20**, **26**, **28**, **33**, and **34**); detailed protocols and V/E versus [analog] plots for determination of analog reactivity parameters with FTase. This material is available free of charge via the Internet at <http://pubs.acs.org>.

olefin of FPP and FTase, and the significance of the length and flexibility of the isoprenoid chain. The targeted compounds were 1,3,1-OPP, 1,2,1-OPP, 2,1,1-OPP, 1,1,1-OPP, 3,1,1-OPP, 2,2,1,1-OPP, where the numbering scheme refers to the methylene units between the double bonds or between the first double bond and diphosphate. By increasing or decreasing the number of methylene units, we generated both more flexible and more strained versions of FPP, which may provide significant information on the degree of flexibility needed for binding to and turnover by FTase. We also wanted to establish the inhibitory potency of compounds displaying a non-allylic diphosphate (2,2,2-OPP and 2,1,2-OPP). These compounds share many common characteristics with FPP, but lack the allylic diphosphate. We do not expect 2,2,2-OPP and 2,1,2-OPP to behave as FTase substrates due to the lower nucleophilicity at C₁; however, we hypothesized that they will act as inhibitors.

The strategy for the synthesis of these compounds was based on the transformation of carbon-oxygen bonds into carbon-carbon bonds developed by Wenkert and colleagues¹¹ and later used by Kocienski and colleagues.¹² This unique transformation is based on the nickel-catalyzed ring opening of both dihydrofurans and dihydropyrans with Grignard reagents to yield stereodefined tri-substituted alkenes. To utilize this powerful procedure, we first alkylated prenyl bromide **1** with either 5-lithio-2,3-dihydrofuran **2** or 6-lithio-2,3-dihydro-2H-pyran (**4**) according to procedures developed by Boeckman and colleagues¹³ (Scheme 1). The alkylated dihydrofuran or dihydropyran was then immediately reacted with MeMgBr and NiCl₂(PPh₃)₂ to produce the homoallylic alcohols **3** or **5** in a 62% and 47% yield respectively.¹² The use of additional 2 equiv of MeMgBr and a longer reaction time was necessary for the construction of **5**.

The iodides corresponding to **3** and **5** (**6** and **7**) were then converted into their organozinc derivatives. Negishi cross-coupling¹⁴ of the organozincs with vinyl iodide **8** followed by deprotection with TBAF afforded **9** and **10** in 47% and 52% overall yield respectively. This sequence of steps allowed us to quickly prepare two frame-shifted alcohols in good yields and with excellent stereoselectivity. We were not able to detect any of the corresponding Z isomer in either case. Diphosphorylation (Scheme 1) generated the two frame-shifted FPP analogs **11** and **12** in 56% and 63% overall yield.

With the completion of 1,2,1-OPP and 1,3,1-OPP, we then targeted the synthesis of two FPP analogs with a shortened central isoprene unit (2,1,1-OPP and 1,1,1-OPP). Both FPP analogs contain a common 1E,4E-pentadiene structural motif. Initially, we planned on coupling the required allyl bromide with the vinyl lithium generated from **8** (Scheme 1). Unfortunately, following lithium-halogen exchange with either *t*-BuLi or *n*-BuLi, we were only able to generate the desired 1E,4E-pentadiene in very poor yield (<10%). Several additives were tried, including copper salts, co-solvents, and Li chelators, all of which did not lead to any improvement in yields. The poor yields were later attributed to either the possibility of a lithium-silicon exchange, or decomposition of the organolithium during preparation and/or attempted coupling reaction.

These unsuccessful attempts prompted us to consider a Stille coupling between stannane **13** and geranyl bromide (**14**) (Scheme 2). Several different variations of the Stille coupling were tried; however, all reactions were found to be contaminated with the same SN2' product

which could not be separated from the desired product. In a third approach, we generated the originally desired vinylolithium via the actions of *n*-BuLi on vinyl-stannane **13** and performed the corresponding coupling with geranyl bromide (**14**) (Scheme 2). Fortunately, this third route was found to be the superior method for generating the 1E,4E-pentadiene motif. We obtained the desired product **15** in a 54% yield. We then applied the same methodology used to generate **15** for the construction of **18** (Scheme 2). With the two alcohols **15** and **18** in hand, the standard chlorination/pyrophosphorylation procedure produced the corresponding diphosphates **19** and **20** in good yields.

We had targeted three frame-shifted FPP compounds that have the same overall length as FPP: 1,3,1-OPP, 3,1,1-OPP, and 2,1,2-OPP. With 1,3,1-OPP (**12**) prepared, we next turned to the synthesis of 3,1,1-OPP (**26**), which would require an alternative approach (Scheme 3). This synthesis began with propargyl alcohol **21**, the precursor to the central isoprene unit of **26**. Following the iodination of **21**, we performed Negishi's ZACA reaction¹⁵ to produce the iodo-alcohol **22** in a 52% yield. We then planned to install the terminal isoprene using the vinyl Grignard reagent **23**.¹⁶ Coupling of the alkyl iodide of **22** with the vinyl Grignard reagent **23** in the presence of CuI produced **24** in a 55% yield. The geranyl analog **24** was then subjected to the same synthetic methodology developed for the synthesis of **19** and **20** (Scheme 2) for the production of 3,1,1-OPP (**26**). Corey-Kim bromination¹⁷ of **24**, displacement of the resulting allylic bromide with the vinyl lithium derivative of **12**, and deprotection afforded alcohol **25** in a 46% yield. Conversion to the diphosphate was achieved as previously described, resulting in the synthesis of 3,1,1-OPP (**26**).

In addition to preparing molecules of similar length to FPP, we also targeted a molecule more similar to geranylgeranyl diphosphate (GGPP) in length. This molecule (2,2,1,1-OPP (**28**), Scheme 4) is only one CH₂ unit shorter than GGPP. To synthesize 2,2,1,1-OPP we started with farnesyl bromide, then performed our two-step vinyl lithium coupling/deprotection sequence (as in Scheme 2). This generated the precursor alcohol (**27**) of 2,2,1,1-OPP in a 54% yield (Scheme 4). The standard Corey-Kim chlorination/ Poulter diphosphorylation procedure¹⁸ was then applied to **27** to yield 2,2,1,1-OPP (**28**) in a 72% yield (Scheme 4).

The last two compounds targeted for synthesis were two FPP analogs containing non-allylic diphosphates (2,1,2-OPP (**33**) and 2,2,2-OPP (**34**), Scheme 4). These molecules were hypothesized to behave as non-substrates due to the significantly decreased leaving group ability of homoallylic diphosphate, that should not allow the prenylation of cysteine found on the CaaX sequence of FTase substrates. Homofarnesol (**32**) was previously synthesized,¹² but not converted into the corresponding diphosphate. Following Kocienski's procedure,¹² we synthesized **32** in good yield from iodide **30**. The diphosphorylation procedure developed by Davisson *et al*.¹⁸ was used to successfully synthesize homofarnesyl diphosphate (**34**, Scheme 4) in excellent yield. The Wenkert-Kocienski homologation protocol allowed for the elongation of geranyl bromide **29** to alcohol **31**, the precursor to 2,1,2-OPP (**33**).

Preliminary evaluation of the eight frame-shifted FPP analogs versus mammalian FTase,^{7,10} revealed that four of the analogues are substrates (**11**, **12**, **26**, **28**) and four of the analogues

are not accepted as substrates (**19**, **20**, **33**, **35**) (Figure 1). A preliminary inhibitory potency assay with the four non-substrates revealed that homofarnesyl diphosphate (**34**) was the only analog with an apparent IC_{50} below 1 μ M. Analogs **19**, **20**, and **33** all exhibit very poor binding to FTase, demonstrating that modest changes to the FPP isoprenoid motif can lead to significant changes in binding. A more detailed evaluation of the four substrates provided further surprising effects of subtle structural changes in the isoprenoid moiety. For example, the conformationally restricted 1E,4E-pentadiene structural motif found in the “tail” of **11**, **12**, and **20** appears to translate into either weak substrates (**11**, **12**) with k_{cat}/K_M values orders of magnitude lower than FPP, or a non-substrate (**20**). This motif appears to destabilize analog binding to FTase, as the increased K_M values for analogs **11** and **12** are consistent with the poor binding exhibited by non-substrate **20**. Conversely, compounds **26** and **28**, with a methylene group removed between the first and second isoprene units, are very good substrates exhibiting k_{cat}/K_M values comparable to FPP with FTase. It should be noted that these comparable k_{cat}/K_M values for **26** and **28** result from ~10-fold decreases in both k_{cat} and K_M as compared to FPP. This indicates that removal of the methylene group impacts both binding and reactivity of analogs **26** and **28**. The case of **28**, with a nor-GGPP structural motif, is particularly surprising. Our results are also in surprising contrast to the observation of substrate plasticity seen with aromatic isoprenoid FTase substrates by the Spielmann group.¹⁹

This study addressed the effects of increasing or decreasing both the length and flexibility of the frame-shifted FPP analogs with respect to FPP. Our results indicate that a key factor in frame-shifted FPP substrate ability was flexibility of the isoprenoid, and in particular a lack of flexibility between the terminal double bonds in the molecule. The “nor-geranylgeranyl” analog **28** is a strikingly effective substrate, in view of the poor substrate ability of GGPP with FTase.²⁰ A rationale for its superior substrate ability to FPP is not clear. However, this analog may be a useful biological tool, as it could enable the prenylation of normally farnesylated proteins with a very close mimic of the geranylgeranyl group, allowing for an exploration of the biological impact of these two closely related modifications.²¹ It has recently been demonstrated that tobacco 5-epi-aristolochene synthase can accept the 2Z,6E-FPP isomer as a substrate, leading to an entirely different set of cyclic sesquiterpene products than the natural 2E,6E-FPP isomer.²² In a similar manner, several of the frame-shifted analogs shown in Figure 1, and in particular diphosphates **12** and **26**, have the potential to exhibit unusual interactions with sesquiterpene cyclases, perhaps leading to unique sesquiterpene products.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

This work was funded by NIH grants R01 CA78819 (RAG) and P30 CA21328 (Purdue University Center for Cancer Research). We thank Dr. Amanda J. Krzysiak (Purdue University) for assistance with the FTase assays, and Professor Carol A. Fierke (Department of Chemistry, University of Michigan) for assistance in obtaining FTase.

References

1. Blagg BS, Jarstfer MB, Rogers DH, Poulter CD. *J. Am. Chem. Soc.* 2002; 124:8846–53. [PubMed: 12137537]
2. Bowman SM, Free SJ. *BioEssays.* 2006; 28:799–808. [PubMed: 16927300]
3. Placzek, AT, Krzysiak, AJ, Gibbs, RA. Chemical Probes of Protein Prenylation.. In: Hrycyna, CA, Bergo, MO, Tamanoi, F, editors. *The Enzymes.* Vol. 30. Academic Press; Burlington: 2011. 91–127.
4. Cane DE, Ikeda H. *Acc. Chem. Res.* 2012; 45(3):463–72. [PubMed: 22039990]
5. Chang MCY, Keasling JD. *Nat. Chem. Biol.* 2006; 2:674–81. [PubMed: 17108985]
6. Miller DJ, Allerhand RK. *Nat. Prod. Rep.* 2012; 29:60–71. [PubMed: 22068697]
7. Rawat DS, Krzysiak AJ, Gibbs RA. *J. Org. Chem.* 2008; 73:1881–1887. [PubMed: 18225915]
8. Placzek AP, Gibbs RA. *Org. Lett.* 2011; 13:3576–3579. [PubMed: 21699139]
9. Clark MK, Scott SA, Wojtkowiak JW, Chirco R, Mathieu P, Reiners JJ Jr. Mattingly RR, Borch RF, Gibbs RA. *J. Med. Chem.* 2007; 50:3274–3282. [PubMed: 17555307]
10. Krzysiak AJ, Rawat DS, Scott SA, Pais JE, Handley M, Harrison ML, Fierke CA, Gibbs RA. *ACS Chem. Biol.* 2007; 2:385–389. [PubMed: 17530735]
11. Wenkert E, Hanna JM, Leftin MH, Michelotti EL, Potts KT, Usifer D. *J. Org. Chem.* 1985; 50:1125–6.
12. Kocienski P, Wadman S, Cooper K. *J. Org. Chem.* 1989; 54:1215–7.
13. Boeckman RK, Bruza KJ. *Tetrahedron.* 1981; 37:3997–4006.
14. Negishi E, Ay M, Gulevich YV, Noda Y. *Tetrahedron Lett.* 1993; 34:1437–1440.
15. Rand CL, Vanhorn DE, Moore MW, Negishi E. *J. Org. Chem.* 1981; 46:4093–4096.
16. Derguiniboumechal F, Linstrumelle G. *Tetrahedron Lett.* 1976:3225–3226.
17. Corey EJ, Takeda M, Kim CU. *Tetrahedron Lett.* 1972:4339–4342.
18. Davisson VJ, Woodside AB, Neal TR, Stremmer KE, Muehlbacher M, Poulter CD. *J. Org. Chem.* 1986; 51:4768–4779.
19. Subramanian T, Liu S, Troutman JM, Andres DA, Spielmann KP. *ChemBioChem.* 2008; 9:2872–2882. [PubMed: 18985644]
20. Yokoyama K, Zimmerman K, Scholten J, Gelb MH. *J. Biol. Chem.* 1997; 272:3944–3952. [PubMed: 9020098]
21. Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, Cox AD, Wilson O, Kirshmeier P, Der CJ. *J. Biol. Chem.* 2008; 283:25150–25163. [PubMed: 18614539]
22. Faraldos JA, O'Malle PE, Dellas N, Noel JP, Coates RM. *J. Am. Chem. Soc.* 2010; 132:4281–4289. [PubMed: 20201526]

Scheme 1.
 Synthesis of 1,2,1-OPP (**11**) and 1,3,1-OPP (**12**).

Scheme 2.
Synthesis of 2,1,1-OPP (**19**) and 1,1,1-OPP (**20**)

Scheme 3.
Synthesis of 3,1,1-OPP (**26**).

Scheme 4.

Synthesis of 2,2,1,1-OPP (**28**), 2,1,2-OPP (**33**), and 2,2,2-OPP (**34**).

Figure 1.
Evaluation of FPP analog substrate ability versus FTase